

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Moser, et al.)	Group Art Unit Unknown
)	
Appl. No.	:	Unknown)	
)	
Filed	:	Herewith)	
)	
For	:	DENDRITIC-LIKE)	
		CELL/TUMOR CELL)	
		HYBRIDS AND)	
		HYBRIDOMAS FOR)	
		INDUCING AN ANTI-TUMOR)	
		RESPONSE)	
)	
Examiner	:	Unknown)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination on the merits, please amend the above-captioned patent application as follows:

IN THE SPECIFICATION:

On page 1, line 10, following the Title of the Invention, please insert the following:

Cross-reference to Related Applications

The present application is a divisonal application of Application Number 09/951,849, filed September 10, 2001, which is a continuation of Application Number 09/049,502, filed March 27, 2001, which is a continuation-in-part of Application Number 09/025,405, filed February 18, 1998, which is a continuation of Application Number 08/625,507, filed March 29, 1996, abandoned, which is a continuation-in-part of Application Number 08/414,480, filed March 31, 1995, abandoned.

Appl. No. : **unknown**
Filed : **Herewith**

On page 5, line 26, before the word "mice" and after the word "cure", please cancel the word "stngeneic" and replace it with the word "syngeneic".

On page 6, line 14, before the word "tumor" and after the word "source", please cancel the word "if" and replace it with the word "of".

On page 22, after line 18 and before the heading "Detailed Description of the Invention" on line 20, please insert the following:

Figure 15

CD8 α^+ , but not CD8 α^- , dendritic cells sensitize T helper-1 type cells in vivo.

Dendritic cells were released for murine spleen fragments and were separated into CD8 α^+ and CD8 α^- . The cells were injected into the footpads of syngeneic mice. Lymph node cells were cultured in the presence of serial dilutions of keyhole limpet hemocyanin (KLH).

Key:

- ◆ untreated mice
- mice receiving unseparated CD8 $\alpha^{+/-}$ cells
- ▲ mice receiving CD8 α^+ cells
- X mice receiving CD8 α^- cells

Figure 15a shows the proliferation of lymph node cells as measured by the thymidine uptake. The X axis is keyhole limpet hemocyanin (KLH) in $\mu\text{g/ml}$, and the Y axis is counts per minute. Lymph node cells from untreated mice did not proliferate upon stimulation with KLH in vitro. Figure 15b shows the interleukin-2 secretion as measured by ELISA. The X axis is keyhole limpet hemocyanin (KLH) in $\mu\text{g/ml}$, and the Y axis is optical density. Figure 15c shows the interferon- γ secretion, as measured by two-site ELISA. The X-axis is keyhole limpet hemocyanin (KLH) in $\mu\text{g/ml}$, and the Y axis is optical density.

On page 40, line 9, please cancel the words "Qiabrane Nylon plus" and substitute the phrase "QIABRANE NYLON PLUS".

On page 40, line 18, please cancel the words "Polymerase Chain Reaction" and substitute the phrase "POLYMERASE CHAIN REACTION".

Appl. No. : **unknown**
Filed : **Herewith**

REMARKS

Amendments were made to correct clerical errors in the specification. No new matter has been added.

Conclusion

Should any issues arise which may delay prosecution of the present application, the Examiner is respectfully invited to contact the undersigned at the telephone number appearing below.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 1/24/02

By: Mark R. Benedict

Mark R. Benedict
Registration No. 44,531
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 721-6323



COPY OF PAPERS
ORIGINALLY FILED

PATENT

Case Docket No. DECLE55.1CP2CD
Date: August 15, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Moser et al.
Appl. No. : 10/057,514
Filed : January 24, 2002
For : DENDRITIC-LIKE
CELL/TUMOR CELL
HYBRIDS AND
HYBRIDOMAS FOR
INDUCING AN ANTI-TUMOR
RESPONSE
Examiner : Unknown
Group Art Unit : 1633

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States
Postal Service as first class mail in an envelope addressed
to United States Patent and Trademark Office, P O. Box
2327, Arlington, VA 22202, on

August 15, 2002

(Date)

Catherine M. Sanders
Catherine M. Sanders, Reg. No. 50,660

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


Dear Sir:

In response to the Notice to File Corrected Application Papers which was mailed on July 16, 2002, enclosed are the following:

- (X) A Response to Notice to File Corrected Application Papers;
- (X) A copy of the Notice to File Corrected Application Papers;
- (X) An Abstract; and
- (X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Catherine M. Sanders
Catherine M. Sanders
Registration No. 50,660
Agent of Record



COPY OF PAPERS
ORIGINALLY FILED

10/057,514 CP2CD

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Moser, et al.)	Group Art Unit 1633
Appl. No.	:	10/057,514)	I hereby certify that this correspondence and all
Filed	:	January 24, 2002)	marked attachments are being deposited with the
For	:	DENDRITIC-LIKE)	United States Postal Service as first-class mail in
		CELL/TUMOR CELL HYBRIDS)	an envelope addressed to: United States Patent
		AND HYBRIDOMAS FOR)	and Trademark Office, P.O. Box 2327,
		INDUCING AN ANTI-TUMOR)	Arlington, VA 22202, on
		RESPONSE)	
Examiner	:	UNKNOWN)	

August 15, 2002

(Date)

Catherine M. Sanders
Catherine M. Sanders, Reg. No. 50,660

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In response to the Notice to File Corrected Application Papers, mailed July 16, 2002, please insert the Abstract attached hereto as page 74 of the application as filed. No new matter is added here with.

Should any issues arise which may delay prosecution of the above-captioned patent application the Examiner is respectfully invited to contact the under-signed agent at the telephone number below. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: August 15, 2002

By: *Catherine M. Sanders*
Catherine M. Sanders
Registration No. 50,660
Agent of Record
2040 Main Street
14th Floor
Irvine, CA 92614
(949) 760-0404

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D C 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/057,514	01/25/2002	Muriel Moser	DECL55.1CP2CD

20995
KNOBBE MARTENS OLSON & BEAR LLP
620 NEWPORT CENTER DRIVE
SIXTEENTH FLOOR
NEWPORT BEACH, CA 92660

CONFIRMATION NO. 4302

FORMALITIES LETTER



OC000000008459885

Date Mailed: 07/16/2002

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE